Literature DB >> 15344672

Glucosamine for osteoarthritis: part I, review of the clinical evidence.

Beth Anne Biggee1, Timothy McAlindon.   

Abstract

Glucosamine is a popular nutritional supplement for OA. This supplement has shown moderate efficacy in meta-analysis and large industry-sponsored clinical trials. However, smaller independent studies have not shown significant benefit. It is difficult to compare these clinical trials due to heterogeneity in trial design, differences in glucosamine products, and differences in osteoarthritic populations being studied. The National Center for Complementary and Alternative Medicine and the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS/NCCAM) have funded a multicenter five arm placebo controlled study called The Glucosamine Arthritis Intervention Trial (GAIT). GAIT spans 24 weeks, enrolling 1588 subjects, at 13 centers comparing the efficacy of glucosamine sulfate, chondroitin sulfate, glucosamine with chondroitin, to placebo and compared to celecoxib for knee OA. This study may have final data in March 2005.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15344672

Source DB:  PubMed          Journal:  Med Health R I        ISSN: 1086-5462


  3 in total

1.  Mesenchymal Stem Cell Therapy for Osteoarthritis: Practice and Possible Promises.

Authors:  Nahid Nasiri; Reihaneh Nateghi; Fatemeh Zarei; Samaneh Hosseini; Mohamdreza Baghaban Eslaminejad
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  A comparison of Kneipp hydrotherapy with conventional physiotherapy in the treatment of osteoarthritis of the hip or knee: protocol of a prospective randomised controlled clinical trial.

Authors:  Martin Schencking; Adriane Otto; Tobias Deutsch; Hagen Sandholzer
Journal:  BMC Musculoskelet Disord       Date:  2009-08-19       Impact factor: 2.362

Review 3.  Curcumin in Autoimmune and Rheumatic Diseases.

Authors:  Melissa Yang; Umair Akbar; Chandra Mohan
Journal:  Nutrients       Date:  2019-05-02       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.